Join us as Rohan and Andrew discuss key takeaways from an impactful ESMO22 in NSCLC. In this episode, we recap the first Phase III data for a KRASG12C inhibitor, long-term follow-up from checkpoint-based regimens, and the first ADC approval in lung.